{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-093914","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.060320+00:00","generated_at":"2026-05-15T19:46:30.987619+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Beam terminates license pact with Bio Palette; Kobe University standby license activated","bullets":["Mutual termination of License Agreement with Bio Palette effective March 2, 2026 due to Bio Palette's planned dissolution.","Standby License Agreement with Kobe University activated, granting Beam exclusive license to base editing patents previously covered.","No future payments due between Beam and Bio Palette under the Termination Agreement or License Agreement.","Beam retains rights to exploit base editing technology for human disease worldwide, minus microbiome field in Asia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-093914","json":"https://secwatch.observer/filing/0001193125-26-093914.json","markdown":"https://secwatch.observer/filing/0001193125-26-093914.md","text":"https://secwatch.observer/filing/0001193125-26-093914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526093914/0001193125-26-093914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526093914/beam-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:46:30.987619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2880d8436033e1cfdd1f1b8e761b3b39d2c9d81e","claim":"Beam Therapeutics Inc. terminated License Agreement with Bio Palette Co., Ltd. (effective 2026-03-02).","evidence_excerpt":"Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) mutually terminated the License Agreement by and between the Company and Bio Palette dated March 27, 2019 (the “License Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526093914/0001193125-26-093914-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Bio Palette Co., Ltd."},{"label":"Effective","value":"2026-03-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}